Developer docs
API playgroundTry for free, no card

Search company profiles

DeCODE Genetics

Full company profile

uuid002ysib

Namestring
DeCODE Genetics
Legal namestring
deCODE genetics
Websiteurl
decode.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

deCODE Genetics is a population-scale human genetics research company headquartered in Reykjavik, Iceland, operating as a wholly-owned subsidiary of Amgen since December 2012. Founded in 1996 by Kári Stefánsson, the company runs what it describes as the most productive human gene discovery engine in the world, built on whole-genome sequencing, proprietary statistical algorithms, and bioinformatics infrastructure. Its defining resource is detailed genetic and medical data from more than 160,000 Icelandic volunteer participants—over half of Iceland's adult population—supplemented by genealogical records spanning over 1,000 years and integration with Iceland's universal healthcare system. Total discovery work extends across approximately 500,000 individuals globally, including cohorts in the US, UK, and Nordic and Baltic countries.

The company's core technology stack combines population-genetics methodology with advanced sequencing modalities (including Oxford Nanopore long-read and methylation analysis) and purpose-built AI tooling, most notably Spliceformer-45k, a transformer-based RNA splicing prediction model that outperforms the SpliceAI benchmark (PR-AUC 0.834 vs 0.820). Its functional outputs are peer-reviewed publications in Nature, Nature Genetics, Cell, and JAMA Cardiology, identifying genetic risk factors and rare variants for cardiovascular disease, cancer, neurological disorders, autoimmune diseases, and metabolic conditions.

Commercially, deCODE does not sell products or services; its single customer is Amgen, which uses deCODE's discoveries to identify and validate drug targets across its therapeutic pipeline. Revenue is internalized through Amgen's R&D budget rather than reported as a standalone line, and academic and healthcare collaborators (including the University of Iceland and Landspítali National Hospital) function as research partners rather than paying customers. The business is effectively a captive, vertically integrated human genetics research unit within Amgen.

Short descriptiontext

deCODE Genetics is a wholly-owned Amgen subsidiary headquartered in Reykjavik, Iceland, that operates a population-scale human gene discovery engine using whole-genome sequencing and proprietary AI to identify genetic risk factors and drug targets for Amgen's pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersReykjavík, Iceland
HQ citystring
Reykjavík
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human genetics research, population genomics analysis, gene discovery engine, genome sequencing research, drug target identification
Industry3 codes
PRIMARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAJAIAK
Public Health Genomics & Sequencing (WGS/Metagenomics) Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
Product category
Population Genetics Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Amgen subsidiary funding
TypeSubscription Recurring
Description

As a wholly-owned subsidiary of Amgen since December 2012, deCODE genetics operates as an integrated part of Amgen's global research and development organization. The company conducts human genetics research to support Amgen's drug discovery and development programs, with funding provided through Amgen's R&D budget rather than generating independent revenue streams.

decode.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

deCODE genetics operates the world's most productive human gene discovery engine, correlating whole-genome sequence variation with phenotype and disease data across roughly 500,000 participants, including more than 160,000 Icelandic volunteers representing over half of Iceland's adult population. It discovers genetic risk factors for common diseases (cardiovascular, cancer, neurological, autoimmune and metabolic) and feeds validated targets into Amgen's drug discovery pipeline. The company does not sell commercial products or services; it conducts research and publishes findings in peer-reviewed journals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Discovery of key genetic risk factors for dozens of common diseases including cardiovascular disease, cancer, neurological disorders, autoimmune diseases, and metabolic conditions
+3 more records
Product overview1 text field

deCODE genetics is a population genetics research company and wholly-owned subsidiary of Amgen. The company does not offer commercial products or services in the traditional sense, but rather conducts human genetics research and gene discovery. Its core activities include analyzing whole genome sequence data from large population cohorts, identifying genetic risk factors for common diseases, and publishing research findings in peer-reviewed journals. Research focus areas include cardiovascular disease, cancer, neurological disorders (Alzheimer's, Parkinson's), autoimmune diseases, and reproductive health. The company leverages detailed genetic and medical information from participants, proprietary statistical algorithms, and genealogical databases to discover genetic variants associated with human disease.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-12-10
Description

Amgen acquired deCODE genetics in December 2012 for its industry-leading ability to identify and validate disease targets in human populations. deCODE operates as a wholly-owned subsidiary and serves as Amgen's central human genetics research facility, enabling Amgen to develop medicines and carry out drug research aimed at tackling serious diseases and serving patients.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Ancestry
TypeDirect peer
Description

Consumer genomics company with very large consented genetic databases used for ancestry and trait/disease association research. Comparable to deCODE as a population-scale human genetics data platform, though focused on consumer genealogy rather than pharma drug-target discovery.

TypeDirect peer
Description

Population-scale human genetics company with one of the largest consented genotype-phenotype databases (millions of customers). Comparable to deCODE in building large-scale genotype-phenotype resources for discovery, though focused on consumer/DTC channels rather than pharma integration.

TypeBroad incumbent
Description

Dominant provider of next-generation sequencing platforms and consumables used by virtually every population-genomics program including deCODE. Comparable as a foundational enabler of deCODE's WGS-based discovery engine, with some overlapping population-genomics initiatives (e.g., Illumina's population sequencing efforts).

TypeDirect peer
Description

Founded by Craig Venter to apply whole-genome sequencing, microbiome, and phenotype data at population scale to drive discovery. Highly comparable to deCODE's population-genomics, WGS-first approach and emphasis on correlating rare variants with disease phenotypes.

TypeBroad incumbent
Description

Established clinical genetics company with a portfolio of germline and somatic tests across oncology, women's health, and mental health. Comparable to deCODE in human genetics expertise, though Myriad focuses on commercialized clinical diagnostic tests rather than population-scale drug-target discovery for a single pharma owner.

TypeEmerging player
Description

Population genomics company operating a CLIA/CAP sequencing lab and a population health platform for health systems and research partners. Comparable to deCODE as a population-genomics platform, though Helix is more commercially focused on clinical/research sequencing services than on pharma target discovery.

7Genomics England
TypeRegional player
Description

UK government-backed initiative running large-scale whole-genome sequencing programs (e.g., 100,000 Genomes Project) and linking sequence data to NHS health records. Comparable to deCODE in leveraging a national-population, healthcare-linked genomics resource for discovery, but operating as a public-sector program in the UK.

TypeDirect peer
Description

Pharma-integrated human genetics research arm (within Regeneron) that sequences and phenotypes large patient cohorts to fuel drug-target discovery. Closest analogue to deCODE: deep pharma backing, large proprietary sequencing programs, and a track record of translating genetic findings into therapeutic programs.

TypeOthers
Description

Large-scale population-based biomedical resource with deep genetic and phenotypic data on ~500,000 UK participants, widely used for gene-disease association studies. Comparable to deCODE as a foundational population-genomics resource feeding pharma and academic discovery, though structured as a public research resource rather than a corporate entity.

TypeEmerging player
Description

Personal genomics company using whole-genome sequencing with privacy-preserving techniques and decentralized data ownership to build a discovery cohort. Comparable to deCODE in emphasizing WGS over genotyping and integrating privacy-preserving data architectures.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DeCODE Genetics

Population Genetics Research Servicesdecode.com

deCODE Genetics is a wholly-owned Amgen subsidiary headquartered in Reykjavik, Iceland, that operates a population-scale human gene discovery engine using whole-genome sequencing and proprietary AI to identify genetic risk factors and drug targets for Amgen's pipeline.

What DeCODE Genetics does

deCODE Genetics is a population-scale human genetics research company headquartered in Reykjavik, Iceland, operating as a wholly-owned subsidiary of Amgen since December 2012. Founded in 1996 by Kári Stefánsson, the company runs what it describes as the most productive human gene discovery engine in the world, built on whole-genome sequencing, proprietary statistical algorithms, and bioinformatics infrastructure. Its defining resource is detailed genetic and medical data from more than 160,000 Icelandic volunteer participants—over half of Iceland's adult population—supplemented by genealogical records spanning over 1,000 years and integration with Iceland's universal healthcare system. Total discovery work extends across approximately 500,000 individuals globally, including cohorts in the US, UK, and Nordic and Baltic countries.

The company's core technology stack combines population-genetics methodology with advanced sequencing modalities (including Oxford Nanopore long-read and methylation analysis) and purpose-built AI tooling, most notably Spliceformer-45k, a transformer-based RNA splicing prediction model that outperforms the SpliceAI benchmark (PR-AUC 0.834 vs 0.820). Its functional outputs are peer-reviewed publications in Nature, Nature Genetics, Cell, and JAMA Cardiology, identifying genetic risk factors and rare variants for cardiovascular disease, cancer, neurological disorders, autoimmune diseases, and metabolic conditions.

Commercially, deCODE does not sell products or services; its single customer is Amgen, which uses deCODE's discoveries to identify and validate drug targets across its therapeutic pipeline. Revenue is internalized through Amgen's R&D budget rather than reported as a standalone line, and academic and healthcare collaborators (including the University of Iceland and Landspítali National Hospital) function as research partners rather than paying customers. The business is effectively a captive, vertically integrated human genetics research unit within Amgen.

DeCODE Genetics firmographics

Firmographics
Name
DeCODE Genetics
Legal name
deCODE genetics
Website
https://decode.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
101–250 employees
Short description
deCODE Genetics is a wholly-owned Amgen subsidiary headquartered in Reykjavik, Iceland, that operates a population-scale human gene discovery engine using whole-genome sequencing and proprietary AI to identify genetic risk factors and drug targets for Amgen's pipeline.
Ownership category
akta.pro rank

DeCODE Genetics industry classification

Industry
Product category
Population Genetics Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAJAIAK
Public Health Genomics & Sequencing (WGS/Metagenomics) Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

  • Human genetics research
  • Population genomics analysis
  • Gene discovery engine
  • Genome sequencing research
  • Drug target identification

Where DeCODE Genetics is headquartered

Location

Headquarters

HQ city
Reykjavík
HQ country
Iceland
HQ region
Europe

Offices1 record

Markets served

DeCODE Genetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

  1. Amgen subsidiary funding: As a wholly-owned subsidiary of Amgen since December 2012, deCODE genetics operates as an integrated part of Amgen's global research and development organization. The company conducts human genetics research to support Amgen's drug discovery and development programs, with funding provided through Amgen's R&D budget rather than generating independent revenue streams.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

DeCODE Genetics product offering

Product offering

Core offering

deCODE genetics operates the world's most productive human gene discovery engine, correlating whole-genome sequence variation with phenotype and disease data across roughly 500,000 participants, including more than 160,000 Icelandic volunteers representing over half of Iceland's adult population. It discovers genetic risk factors for common diseases (cardiovascular, cancer, neurological, autoimmune and metabolic) and feeds validated targets into Amgen's drug discovery pipeline. The company does not sell commercial products or services; it conducts research and publishes findings in peer-reviewed journals.

Product overview

deCODE genetics is a population genetics research company and wholly-owned subsidiary of Amgen. The company does not offer commercial products or services in the traditional sense, but rather conducts human genetics research and gene discovery. Its core activities include analyzing whole genome sequence data from large population cohorts, identifying genetic risk factors for common diseases, and publishing research findings in peer-reviewed journals. Research focus areas include cardiovascular disease, cancer, neurological disorders (Alzheimer's, Parkinson's), autoimmune diseases, and reproductive health. The company leverages detailed genetic and medical information from participants, proprietary statistical algorithms, and genealogical databases to discover genetic variants associated with human disease.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Discovery of key genetic risk factors for dozens of common diseases including cardiovascular disease, cancer, neurological disorders, autoimmune diseases, and metabolic conditions
  • +3 more outcomes

Companies that use DeCODE Genetics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

DeCODE Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

DeCODE Genetics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AmgencoreStrategic or Co-development Partner · 10 December 2012Amgen acquired deCODE genetics in December 2012 for its industry-leading ability to identify and validate disease targets in human populations. deCODE operates as a wholly-owned subsidiary and serves as Amgen's central human genetics research facility, enabling Amgen to develop medicines and carry out drug research aimed at tackling serious diseases and serving patients.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

DeCODE Genetics competitors and assessment

Company assessment

Direct peers

  • Ancestry: Consumer genomics company with very large consented genetic databases used for ancestry and trait/disease association research. Comparable to deCODE as a population-scale human genetics data platform, though focused on consumer genealogy rather than pharma drug-target discovery.
  • 23andMe: Population-scale human genetics company with one of the largest consented genotype-phenotype databases (millions of customers). Comparable to deCODE in building large-scale genotype-phenotype resources for discovery, though focused on consumer/DTC channels rather than pharma integration.
  • Human Longevity Inc. Founded by Craig Venter to apply whole-genome sequencing, microbiome, and phenotype data at population scale to drive discovery. Highly comparable to deCODE's population-genomics, WGS-first approach and emphasis on correlating rare variants with disease phenotypes.
  • Regeneron Genetics Center: Pharma-integrated human genetics research arm (within Regeneron) that sequences and phenotypes large patient cohorts to fuel drug-target discovery. Closest analogue to deCODE: deep pharma backing, large proprietary sequencing programs, and a track record of translating genetic findings into therapeutic programs.

Broad incumbents

  • Illumina: Dominant provider of next-generation sequencing platforms and consumables used by virtually every population-genomics program including deCODE. Comparable as a foundational enabler of deCODE's WGS-based discovery engine, with some overlapping population-genomics initiatives (e.g., Illumina's population sequencing efforts).
  • Myriad Genetics: Established clinical genetics company with a portfolio of germline and somatic tests across oncology, women's health, and mental health. Comparable to deCODE in human genetics expertise, though Myriad focuses on commercialized clinical diagnostic tests rather than population-scale drug-target discovery for a single pharma owner.

Emerging players

  • Helix: Population genomics company operating a CLIA/CAP sequencing lab and a population health platform for health systems and research partners. Comparable to deCODE as a population-genomics platform, though Helix is more commercially focused on clinical/research sequencing services than on pharma target discovery.
  • Nebula Genomics: Personal genomics company using whole-genome sequencing with privacy-preserving techniques and decentralized data ownership to build a discovery cohort. Comparable to deCODE in emphasizing WGS over genotyping and integrating privacy-preserving data architectures.

Regional players

  • Genomics England: UK government-backed initiative running large-scale whole-genome sequencing programs (e.g., 100,000 Genomes Project) and linking sequence data to NHS health records. Comparable to deCODE in leveraging a national-population, healthcare-linked genomics resource for discovery, but operating as a public-sector program in the UK.

Others

  • UK Biobank: Large-scale population-based biomedical resource with deep genetic and phenotypic data on ~500,000 UK participants, widely used for gene-disease association studies. Comparable to deCODE as a foundational population-genomics resource feeding pharma and academic discovery, though structured as a public research resource rather than a corporate entity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

DeCODE Genetics social profiles

Digital presence

DeCODE Genetics compliance and trust

Trust signal

Compliance1 record

DeCODE Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DeCODE Genetics leadership team

Management profile

Number of profiles

Profiles12 records

DeCODE Genetics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

DeCODE Genetics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DeCODE Genetics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeCODE Genetics

What does DeCODE Genetics do?

deCODE genetics operates the world's most productive human gene discovery engine, correlating whole-genome sequence variation with phenotype and disease data across roughly 500,000 participants, including more than 160,000 Icelandic volunteers representing over half of Iceland's adult population. It discovers genetic risk factors for common diseases (cardiovascular, cancer, neurological, autoimmune and metabolic) and feeds validated targets into Amgen's drug discovery pipeline. The company does not sell commercial products or services; it conducts research and publishes findings in peer-reviewed journals.

Is DeCODE Genetics a public or private company?

DeCODE Genetics is a private company. It is classified as corporate owned and is currently operating.

When was DeCODE Genetics founded?

DeCODE Genetics was founded in 1996. It employs 101 to 250 people.

Where is DeCODE Genetics based?

DeCODE Genetics is headquartered in Reykjavík, Iceland, in the Europe region.

How does DeCODE Genetics make money?

One revenue line is on record: amgen subsidiary funding.

Who are DeCODE Genetics's main competitors?

Direct peers on record are Ancestry, 23andMe, Human Longevity Inc. and Regeneron Genetics Center. Broad incumbents are Illumina and Myriad Genetics. Emerging players are Helix and Nebula Genomics. Genomics England is listed as a regional player. UK Biobank is listed as an others.

Does DeCODE Genetics have an API?

No public API is recorded for DeCODE Genetics.

What industry is DeCODE Genetics in?

DeCODE Genetics's product category is Population Genetics Research Services. Its primary akta.pro industry code is HLAAANAL, Population Genomics & Preventive Precision Health Programs, with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FAZ.NETResistente Hypertonie: Wenn Blutdruck nicht sinktResearchers investigated the genetic background of resistant hypertension, a condition where up to 18% of patients do not respond to standard medication. The study utilized data from population-wide databases including the UK Biobank and the Icelandic company deCODE to identify potential causes such as adrenal cortex overactivity.JournalStar.com8 Icelandic companies driving the future of life sciencesEight Icelandic life sciences companies are profiled, including Alvotech, deCODE Genetics, and Kerecis, which develop biosimilars, genetic insights, and wound treatments. The sector grew 23% over five years, with over 80% of companies clustered in Reykjavík. The companies aim to address global health challenges through innovation.FortuneThe CEO who loves AI autodidacts — and desperately needs his expertsAmgen CEO Bob Bradway has been pursuing an AI strategy since 2012, when the company acquired Icelandic genomics firm DeCODE Genetics to build a data-driven drug discovery capability, and has since developed proprietary protein folding models and zero-shot antibody design. The company reports tangible results including 50% faster selection of drug candidates for clinical development, production line clearance reduced from 30 minutes to approximately two minutes per batch, and significantly more efficient trial enrollment. Bradway is now positioning Amgen for agentic AI deployment in 2026, arguing that AI will liberate rather than replace the company's expert scientists by automating administrative tasks.SCC OnlineDon’t Let the “Gene” Out of the BottleThis article is a legal analysis examining genetic data protection under India's Digital Personal Data Protection Act (DPDPA) and comparing it with the EU's GDPR, focusing on compliance requirements for hospitals and biotech companies. It discusses India's government initiatives involving genetic data processing, including Gujarat's tribal genome sequencing project, the National Biobank, and AIIMS Jammu's Centre for Advanced Genomics. The article cites two case studies of genetic data mishandling—deCODE Genetics in Iceland and 23andMe's £2.31 million fine by UK and Canadian regulators—illustrating the risks of inadequate protection and arguing that genetic data warrants heightened safeguards despite not being explicitly classified as sensitive under Indian law.PR NewswireLas variantes raras de pérdida de función en HECTD2 y AKAP11 confieren un riesgo de trastorno bipolarScientists from deCODE Genetics, a subsidiary of Amgen, have identified rare loss-of-function variants in two genes (HECTD2 and AKAP11) that are associated with increased risk of bipolar disorder, according to a study published in Nature Genetics. The research analyzed genomic sequencing data from Iceland and the UK Biobank, along with data from the Bipolar Exomes study. The findings suggest that these gene products, along with GSK3β (a protein inhibited by lithium), represent promising targets for developing improved treatments for bipolar disorder.PR NewswireDes variantes rares de perte de fonction dans HECTD2 et AKAP11 confèrent un risque de trouble bipolaireScientists from deCODE genetics, a wholly-owned subsidiary of Amgen, published research in Nature Genetics identifying rare loss-of-function variants in two genes, HECTD2 and AKAP11, that are associated with bipolar disorder risk. The study analyzed whole-genome sequencing data from Iceland and the UK Biobank, with replication using Bipolar Exomes data. The gene products of HECTD2 and AKAP11 interact with GSK3β, a protein inhibited by lithium, positioning these genes and GSK3β as promising targets for developing new bipolar disorder treatments.PR NewswireRare loss-of-function variants in HECTD2 and AKAP11 confer a risk of bipolar disorderScientists at deCODE genetics, a subsidiary of Amgen, published research in Nature Genetics identifying associations between rare loss-of-function variants in two genes (HECTD2 and AKAP11) and bipolar disorder using whole genome sequencing data from Iceland and the UK Biobank. The study found that both gene products interact with GSK3β, a protein inhibited by lithium, the primary mood stabilizer used to treat bipolar disorder. These findings point to specific cellular pathways involved in bipolar disorder and suggest AKAP11, HECTD2, and GSK3β as promising targets for developing new treatments.PR NewswiredeCODE genetics: Mapa completo de recombinación del genoma humano, un gran paso en la genéticaScientists at deCODE genetics/Amgen published a complete map of human genome recombination in Nature, representing a major advancement in understanding how DNA mixes during reproduction and its impact on genetic diversity, health, and fertility. The research, spanning 25 years of work, reveals key differences between men and women in recombination patterns and shows that mutations correlate with DNA mixing regions, offering new insights into why infertility affects approximately one in ten couples globally. The findings could improve fertility treatments and help diagnose pregnancy complications, while also advancing understanding of human evolution and individual genetic differences.